Stockscreener 앱 받기
27.96
3.79%
-1.10
시간 외 거래:
27.96
전일 마감가:
$29.06
열려 있는:
$29.3
하루 거래량:
102.14K
Relative Volume:
1.03
시가총액:
$295.01M
수익:
$96.10M
순이익/손실:
$-31.96M
주가수익비율:
-6.9437
EPS:
-4.0267
순현금흐름:
$-25.27M
1주 성능:
-4.05%
1개월 성능:
+6.80%
6개월 성능:
+82.03%
1년 성능:
+270.82%
1일 변동 폭
$27.52
$29.99
1주일 범위
$26.33
$30.13
52주 변동 폭
$5.26
$31.97
바이오데식스 Stock (BDSX) Company Profile
명칭
Biodesix Inc
전화
303-417-0500
주소
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX vs TMO, DHR, NTRA, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
27.96 | 307.04M | 96.10M | -31.96M | -25.27M | -4.0267 |
TMO
Thermo Fisher Scientific Inc
|
656.58 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.61 | 150.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
400.65 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
169.33 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
436.43 | 42.59B | 3.77B | 449.25M | 240.68M | 7.8556 |
바이오데식스 Stock (BDSX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-27 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-05-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-09-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-26 | 개시 | Craig Hallum | Buy |
| 2024-05-13 | 개시 | TD Cowen | Buy |
| 2024-05-03 | 개시 | Lake Street | Buy |
| 2021-11-17 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-23 | 개시 | BTIG Research | Buy |
| 2020-11-23 | 개시 | Canaccord Genuity | Buy |
| 2020-11-23 | 개시 | Morgan Stanley | Overweight |
| 2020-11-23 | 개시 | William Blair | Outperform |
모두보기
바이오데식스 주식(BDSX)의 최신 뉴스
Biodesix Inc (BDSX) Shares Fall 4.2% -- What GF Score of 50 Tells Investors - GuruFocus
Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests - Yahoo Finance
HC Wainwright & Co. maintains Buy rating on Biodesix, $38 price target - TradingView
Biodesix Stock Price Forecast. Should You Buy BDSX? - StockInvest.us
Biodesix, Inc. (BDSX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease Monitoring - marketscreener.com
Biodesix, Inc. Advances Two Complementary Approaches to Molecular Residual Disease Monitoring - marketscreener.com
Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher - Yahoo Finance
Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher - Investing.com
Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher By Investing.com - Investing.com India
Biodesix Announces Progress on Tumor-Informed and Tumor-Naïve MRD Programs with Bio-Rad and Thermo Fisher - Quiver Quantitative
Biodesix Advances Two Complementary Approaches To Molecular Residual Disease (Mrd) Monitoring - TradingView
After cancer treatment, monitoring may reach patients without tumor tissue - Stock Titan
Biodesix (BDSX) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Biodesix, Inc.(NasdaqGM: BDSX) added to S&P Global BMI Index - marketscreener.com
Wall Street Analysts Think Biodesix (BDSX) Could Surge 31.91%: Read This Before Placing a Bet - Eastern Progress
Biodesix (BDSX) Stock Gets Fair Value Boost On Revenue And Margin Optimism - Yahoo Finance
Biodesix Inc (NASDAQ: BDSX) Stock Price, News & Analysis - kalkine.ca
Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings - Stock Titan
A Look at Biodesix Inc (BDSX) After 3.5% Gain -- GF Value $21.14 vs Price $26.96 - GuruFocus
Opaleye Management Inc. Cuts Position in Biodesix, Inc. $BDSX - marketbeat.com
Biodesix: Growing Fast While Trading Below Many Diagnostics Peers (NASDAQ:BDSX) - Seeking Alpha
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Recommendation of "Moderate Buy" by Analysts - marketbeat.com
BlackRock Inc. Invests $970,000 in Biodesix, Inc. $BDSX - marketbeat.com
What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now? - Eastern Progress
Biodesix to Participate in Upcoming Investor Conferences - The Manila Times
BioDesix (NASDAQ:BDSX) Passes Minervini Trend Template but Setup Quality Remains Weak - ChartMill
Wall Street Analysts See a 26.72% Upside in Biodesix (BDSX): Can the Stock Really Move This High? - Yahoo Finance
Biodesix Inc (BDSX) Stock Up 9.0% but GF Value Says Overvalued -- GF Score: 51/100 - GuruFocus
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect? - qz.com
BDSX: Biodesix Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? - Prime Publishers, Inc.
Biodesix (BDSX) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Stock Loses 5.91% in the Latest SessionCEO Earnings Statement - vinanet.vn
Biodesix (BDSX) Results Check: The Bottom-Line Figure Beats Its Comparison; After Earnings: The Market Price Declines 3.91% in Latest TradingGuidance Accuracy Score - vinanet.vn
46,989 Shares in Biodesix, Inc. $BDSX Purchased by GSA Capital Partners LLP - MarketBeat
AIGH Capital Management LLC Acquires New Stake in Biodesix, Inc. $BDSX - MarketBeat
Biodesix (BDSX) Edges Higher at $24.0 as Bulls Defend Key SupportVol Target Rebalance - vinanet.vn
Walleye Capital LLC Makes New $1.68 Million Investment in Biodesix, Inc. $BDSX - MarketBeat
Sei Investments Co. Makes New Investment in Biodesix, Inc. $BDSX - MarketBeat
BDSX Q2 2026 Earnings: EPS Beats Estimates by 22.85% as Loss NarrowsEarnings Preview - vinanet.vn
BDSX | Biodesix, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Biodesix director Jack Schuler buys company stock, valued at $366,991 By Investing.com - Investing.com Australia
Biodesix director Jack Schuler buys company stock, valued at $366,991 - Investing.com
BDSX Q2 2026 Earnings: Narrower Loss Beats Estimates as Shares Dip 1.78Earnings Yield Spread - Vinanet
Biodesix (NASDAQ:BDSX) Director Jack Schuler Buys 15,000 Shares of Stock - MarketBeat
Biodesix Insider Bought Shares Worth $366,992, According to a Recent SEC Filing - marketscreener.com
Biodesix Inc (BDSX) major holder Jack W. Schuler buys 15,000 shares - Stock Titan
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Biodesix director Jack Schuler buys $665,940 in company stock By Investing.com - Investing.com Australia
Biodesix (NASDAQ:BDSX) Director Jack Schuler Purchases 13,700 Shares of Stock - MarketBeat
Insider Buying: Biodesix (NASDAQ:BDSX) Director Purchases 13,900 Shares - MarketBeat
바이오데식스 (BDSX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오데식스 주식 (BDSX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SCHULER JACK W | Emeritus Director |
Aug 10 '26 |
Buy |
24.25 |
13,900 |
337,029 |
527,110 |
| SCHULER JACK W | Emeritus Director |
Aug 11 '26 |
Buy |
24.01 |
13,700 |
328,911 |
540,810 |
| Pestano Gary Anthony | Chief Development Officer |
Feb 23 '26 |
Sale |
12.78 |
556 |
7,103 |
10,359 |
| O'Kane Kieran | Chief Commercial Officer |
Feb 23 '26 |
Sale |
12.78 |
535 |
6,835 |
9,819 |
| Cowie Robin Harper | CFO, Sec'y & Treasurer |
Feb 23 '26 |
Sale |
12.78 |
535 |
6,835 |
16,231 |
| Vazquez Chris | Chief Accounting Officer |
Feb 23 '26 |
Sale |
12.78 |
211 |
2,696 |
1,586 |
| Hutton Scott | President & CEO |
Feb 23 '26 |
Sale |
12.78 |
1,490 |
19,036 |
48,767 |
0.99%
0.56%
자본화:
|
볼륨(24시간):